Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Qian Zhang, MD
- Phone Number: 8613120012579
- Email: zhangqianchina@yahoo.com
Study Contact Backup
- Name: Chaofan Zeng, MD
- Phone Number: 8613693276138
- Email: zchf723@163.com
Study Locations
-
-
-
Beijing, China, 100070
- Recruiting
- Beijing Tiantan Hospital
-
Contact:
- Qian Zhang, MD
- Phone Number: 8613120012579
- Email: zhangqianchina@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease.
- Please sign the informed consent form.
- Participants must be between 18 and 60 years of age.
Exclusion Criteria:
- Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome.
- Individuals younger than 18 years or older than 60 years.
- Those with contraindications for magnetic resonance imaging.
- Patients who are unable to complete cognitive brain assessments
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in composite score of neurocognitive function at 6 months after treatment.
Time Frame: 6 months during follow-up
|
The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 6 months after treatment.
|
6 months during follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in composite score of neurocognitive function at 12 and 24 months after treatment.
Time Frame: 12 and 24 months during follow-up
|
The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 12 and 24 months after treatment.
|
12 and 24 months during follow-up
|
|
Rate of participants experiencing cerebrovascular events (TIA, infarction and hemorrhage) within 6, 12 and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in neurological function assessed by modified Rankin scale (mRS) at 6, 12, and 24 months following treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in neurological function assessed by National Institute of Health stroke scale (NIHSS) at 6, 12, and 24 months following treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in cerebral blood perfusion assessed by arterial spin labeling (ASL) at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Hemodynamic changes at the terminal segment of internal carotid artery assessed by computational fluid dynamics (CFD) at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Morphological changes at the terminal segment of internal carotid artery and middle cerebral artery wall assessed by high-resolution vessel wall imaging at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Power Spectral Density (PSD) assessed by electroencephalography (EEG) at 6, 12, and 24 months after treatment will be measured.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Phase Locking Value (PLV) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Phase-Lag Index (PLI) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Degree Centrality assessed by multimodal MRI at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Clustering Coefficient assessed by multimodal MRI at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Structural Connectivity Strength assessed by multimodal MRI at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
|
|
Changes in Network Density assessed by multimodal MRI at 6, 12, and 24 months after treatment.
Time Frame: 6, 12 and 24 months during follow-up
|
6, 12 and 24 months during follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Mental Disorders
- Neurocognitive Disorders
- Cognition Disorders
- Arterial Occlusive Diseases
- Intracranial Arterial Diseases
- Carotid Artery Diseases
- Cerebral Arterial Diseases
- Cognitive Dysfunction
- Moyamoya Disease
Other Study ID Numbers
Other Study ID Numbers
- KY2024-112-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.